Introduction
============

Invasive fungal infections (IFIs) are deadly infections requiring rapid diagnosis and treatment. In the People's Republic of China, the IFI incidence ranges from 4% to 41% depending on patient population and underlying conditions.[@b1-ceor-8-275] *Candida* spp. are the predominant organisms identified in patients with IFIs in the People's Republic of China; however, the incidence of *Aspergillus* infections is increasing.[@b1-ceor-8-275] Patients at risk for IFIs include transplant recipients and those with hematological malignancies or human immunodeficiency virus.[@b2-ceor-8-275]

Empiric antifungal therapy is often initiated in patients with persistent and/or recurrent fevers unresponsive to broad-spectrum antibacterial therapy for 72 hours. Early use of companion diagnostics, or a diagnostic-driven (DD) approach, can potentially identify IFIs prior to antifungal treatment initiation. Patients treated using a DD treatment approach are initiated on antifungal therapy based not only on clinical suspicion but also on a positive diagnostic evaluation. A benefit of a DD treatment approach is lower costs due to reduction of unnecessary antifungal treatment. Results from several studies suggest that a DD or preemptive approach compared to an empiric approach may be beneficial in patients with suspected IFIs.[@b3-ceor-8-275]--[@b7-ceor-8-275]

Given the high mortality reported for IFIs, specifically invasive aspergillosis, and the increasing incidence of aspergillosis in the People's Republic of China, we adapted a pharmacoeconomic model to assess the impact of a DD compared to an empiric approach on costs and outcomes in neutropenic patients with suspected IFIs in the following four geographically representative Chinese cities: Beijing, Chengdu, Guangzhou, and Shanghai.

Methods
=======

A previously published decision-analytic model[@b8-ceor-8-275] was adapted to reflect costs and resource utilization in Beijing, Chengdu, Guangzhou, and Shanghai, the People's Republic of China. A DD or an empiric approach was used to treat patients with persistent or recurrent febrile neutropenia. Patients treated using a DD approach following clinical suspicion of an IFI underwent galactomannan (GM) testing and/or a computed tomography (CT) scan to direct initiation of antifungal therapy. Patients treated using an empiric approach were initiated on antifungal therapy based on clinical suspicion alone. Antifungal treatment was assumed initiated at the same time regardless of approach.[@b8-ceor-8-275]

Model structure
---------------

The previously published decision model (UK perspective) that we adapted was designed as a simple decision tree over a time horizon of 5 months.[@b8-ceor-8-275] In this adapted model, a hypothetical cohort of 1,000 neutropenic patients at risk of IFIs entered the decision tree and were treated using either a DD or an empiric approach ([Figure 1](#f1-ceor-8-275){ref-type="fig"}). Patients treated using a DD approach received antifungal therapy following both clinical suspicion and a positive diagnostic test result suggestive of an IFI. Patients treated using an empiric approach received antifungal therapy following clinical suspicion of an IFI alone. Patients treated using an empiric approach could ultimately have a proven, probable, or no fungal infection. Following initiation of antifungal therapy regardless of approach, patients survived or died based on epidemiological and clinical data obtained from published literature.[@b9-ceor-8-275] Antifungal therapies evaluated in both the DD and empiric branches included caspofungin, itraconazole, and voriconazole; therapies evaluated were recommended by the Chinese clinical experts interviewed for this study.

Patient population
------------------

The hypothetical study population for this model adaptation included patients older than 18 years with a hematological malignancy scheduled for chemotherapy or autologous/allogeneic stem cell transplantation with an expected neutrophil count \<500 cells/mm^3^ for at least 10 days.[@b3-ceor-8-275]--[@b7-ceor-8-275] We assumed that all patients entering the model were not previously diagnosed with a proven or probable IFI or treated with an antifungal therapy within the last 6 months.

Clinical variables
------------------

Overall mortality, IFI incidence, IFI identification by the empiric approach, and IFI-related mortality data were incorporated from the global model.[@b8-ceor-8-275] Survival rates were generated based on the proportion of patients with identified and appropriately treated IFIs. Treatment patterns and therapy duration for both approaches were based on the opinion of three to five renowned clinicians practicing at top hospitals in each Chinese city.

The primary clinical measure required to estimate the costs and outcomes associated with each treatment approach was IFI incidence within a particular clinical setting. An IFI incidence of 10.9% (95% confidence interval \[CI\]: 9%--13%) was assumed based on a patient population treated with myelosuppressive chemotherapy for hematological malignancies or following autologous stem cell transplant in a German tertiary care center[@b9-ceor-8-275] and confirmed by our Chinese clinical experts.

Predicted survival following a DD or an empiric approach was the primary clinical outcome of interest. Mortality inputs were obtained from epidemiological and clinical studies due to a lack of data from head-to-head comparative antifungal treatment studies.[@b9-ceor-8-275],[@b10-ceor-8-275] Specifically, overall mortality during the years 2002--2006 was reported as 10.7% (95% CI: 9%--13%) and IFI-related mortality as 28.6% (95% CI: 19%--39%) in a population of patients treated with myelosuppressive chemotherapy for hematological malignancies or following autologous stem cell transplantation.[@b9-ceor-8-275] A 28.6% increase in mortality was assumed for patients with IFIs since IFI deaths would only occur in patients with IFIs. Given this assumption, the overall mortality was adjusted to be specific to patients with and without IFIs ([Table 1](#t1-ceor-8-275){ref-type="table"}).

Additionally, the model examined the treatment effect of itraconazole, caspofungin, or voriconazole administration on overall survival. Results from a multivariable analysis in patients with IFIs showed a significant improvement in overall survival with voriconazole and caspofungin compared to amphotericin (hazard ratio: 0.589; 95% CI: 0.362--0.959; *P*=0.033).[@b9-ceor-8-275] Results from a separate analysis showed similar mortality rates for itraconazole and amphotericin.[@b10-ceor-8-275] Therefore, specific morality values for itraconazole, caspofungin, and voriconazole were calculated using amphotericin-based agents as a reference comparator ([Table 1](#t1-ceor-8-275){ref-type="table"}).

Costs and health care resource use
----------------------------------

Health care resource unit costs in 2014 Chinese Yuan (¥; July 2014: 1 Chinese Yuan =0.1612 US dollars) were collected for each Chinese city evaluated. Three to five clinical experts on IFI treatment at major tier-3A hospitals from the four representative cities were recruited and surveyed through a series of face-to-face interviews to determine actual resource utilization. Per-patient antifungal therapy costs were estimated by multiplying the daily drug acquisition costs by treatment duration ([Table 2](#t2-ceor-8-275){ref-type="table"}). The model incorporated additional resources utilized in IFI patient management as determined through the physician surveys ([Table 3](#t3-ceor-8-275){ref-type="table"}). Analysis of survey results showed a lack of differentiation in laboratory test utilization between the DD and the empiric approaches. This lack of differentiation between treatment approaches was previously reported.[@b11-ceor-8-275] Hepatotoxicity was identified as the only adverse event requiring intensive treatment and resource use and therefore included in the model. Antifungal hepatotoxicity rates were obtained from the drug labels.[@b12-ceor-8-275]--[@b14-ceor-8-275] The estimated cost to treat one case of hepatotoxicity was ¥400.

Model analyses
--------------

The model estimates total costs, death avoided, and incremental cost-effectiveness ratios per death avoided for the DD and the empiric approaches from a third-party payer perspective in 2014 Chinese ¥. The base-case scenario incorporates real-world GM test and CT scan utilization rates. The CT scan and GM test sensitivity was averaged and applied to the DD treatment arm.[@b15-ceor-8-275],[@b16-ceor-8-275] A scenario analysis was conducted utilizing a GM test rate of 100% for the DD arm only, consistent with a recently published guideline.[@b17-ceor-8-275]

One-way sensitivity analyses were performed to assess the impact of each parameter on the incremental cost per death avoided. Second-order Monte Carlo simulations were also conducted to examine the robustness of model results and the effects of parameter uncertainty on study findings.

Results
=======

Cost-effectiveness analysis (base-case results)
-----------------------------------------------

Cost results obtained from our model varied from ¥3,232 in Shanghai to ¥8,489 in Guangzhou for the DD and from ¥4,331 in Shanghai to ¥9,795 in Guangzhou for the empiric approach ([Table 4](#t4-ceor-8-275){ref-type="table"}). Fewer patients in the DD (5.7%) than empiric (9.8%) arm received antifungal treatment, although the number of patients diagnosed with IFIs was higher in the DD (5.7%) than empiric (3.3%) arm. Estimated survival rates ranged from 91.38% to 91.72% in the DD and 90.24% to 91.19% in the empiric treatment arms. As a result, the DD compared to empiric approach was cost saving (ie, cost less with similar mortality) to health care payers in the People's Republic of China.

Scenario analysis
-----------------

Results from the scenario analysis, in which GM test utilization was assumed to be 100%, show higher total costs per patient for both the DD and the empiric approaches compared to the base-case analysis, reflecting an increase in GM testing costs and number of IFIs diagnosed. For this scenario, total treatment costs per patient for the DD compared to the empiric approach, respectively, were ¥3,535 and ¥4,847 in Shanghai, ¥4,118 and ¥5,245 in Beijing, ¥5,463 and ¥6,389 in Chengdu, and ¥9,762 and ¥10,351 in Guangzhou. The number of diagnosed IFIs was higher in this scenario analysis (6.7%) than the base-case scenario (5.7%) for all four cities as a result of the higher diagnostic test sensitivity with 100% GM test utilization. Thus, more patients received antifungal treatment in this scenario (DD, 6.7% vs empiric approach, 11.4%) than the base-case (DD, 5.7% vs empiric approach, 9.8%).

One-way sensitivity analysis
----------------------------

Univariate one-way sensitivity analysis was conducted in the adapted Shanghai model to test the impact of parameter variations on the cost-effectiveness of a DD approach. The incremental cost per death avoided was most sensitive to changes in diagnostic test sensitivity, followed by IFI-related mortality ([Figure 2](#f2-ceor-8-275){ref-type="fig"}). Cost savings per death avoided increased from ¥108 to ¥1,599 as the diagnostic test sensitivity increased from 47.5% to 95%. The DD approach remained dominant, regardless of variables changed. Dominance of the DD over the empiric approach was observed from the negative incremental cost-effectiveness ratios in terms of per death avoided in all cases. Results were similar for the other three cities (data not shown).

Probabilistic sensitivity analysis
----------------------------------

Second-order Monte Carlo simulations, in which all model parameters were varied, were run 10,000 times in order to capture stability in the results and the effects of parameter uncertainty on study findings for Shanghai. Results from this analysis showed that a DD approach was cost saving in 88.45% and an empiric approach in 0.06% of simulations ([Figure 3](#f3-ceor-8-275){ref-type="fig"}).

Discussion
==========

Neutropenic patients with persistent fever following 72 hours of empiric antibiotic therapy are typically treated empirically for IFIs. Not all of these empirically treated patients will have IFIs, resulting in unnecessary administration of antifungal therapies and an increased risk of developing serious adverse events. Patients treated using a DD approach receive antifungal therapy following not only clinical suspicion but also diagnostic confirmation of fungal infections.

Results from our analyses found that a DD compared to an empiric treatment approach is cost saving (ie, cost less with similar mortality) from the point of view of the third-party payer (eg, Bureau of Human Resources and Social Security) in four Chinese cities (Beijing, Chengdu, Guangzhou, and Shanghai). In general, the increase in diagnostic test costs incurred was offset by a decrease in antifungal therapy costs due to identification of a more targeted treatment population in the DD (5.7%) than the empiric (9.8%) arm. Cost savings ranged from a low of ¥969.96 per patient in Beijing to a high of ¥1,305.28 per patient in Guangzhou. Results from one-way sensitivity analyses were most sensitive to changes in diagnostic test sensitivity followed by IFI-related mortality.

Differences in GM test utilization were evident among the four cities evaluated, potentially reflecting differences in test availability and acceptance. In Shanghai and Beijing, use of GM testing was high with 94% or more of patients treated using a DD approach receiving four to seven GM tests. In Chengdu and Guangzhou, \<50% of patients received one to two GM tests. The lower use of GM testing in Chengdu and Guangzhou compared to Beijing and Shanghai is potentially reflective of test availability. Although GM testing is used in clinical practice in large cities, it is not yet available in many provinces.

Use of CT scans in a DD approach in the People's Republic of China was common with 100% of patients in Shanghai, Beijing, and Guangzhou and 90% in Chengdu undergoing at least one CT scan. Combined use of GM tests and CT scans is consistent with recent guideline recommendations and should improve overall test sensitivity.[@b18-ceor-8-275] However, until GM testing becomes universally available throughout the People's Republic of China, CT scans will be the predominant test utilized in a DD approach. To reflect the differences in resource utilization among these four cities, we conducted sensitivity analyses to assess the impact of varying the percentages of patients receiving these two tests on our model results, which appeared robust to the change.

We found that the use of diagnostic tests to aid in the diagnosis of IFI in the People's Republic of China varied widely and at times blurred the distinction between the DD and the empiric treatment approaches. Based on results obtained from the Chinese clinical expert interviews, we opted to only include GM testing and CT scans in our model. Although other biomarker screening tests such as beta-[d]{.smallcaps}-glucan and polymerase chain reaction tests are used to identify patients with invasive aspergillosis in other parts of the world, these tests are rarely utilized in the People's Republic of China and therefore were not incorporated into the model.

Results from this Chinese pharmacoeconomic model adaptation are similar to those reported for the UK[@b8-ceor-8-275] and Spain.[@b19-ceor-8-275] Lower total costs were reported for patients treated using a DD (£1,561) compared to an empiric (£2,302) approach in the UK. Although per-patient medical costs were higher for the cohort treated using a DD compared to an empiric approach (£734 vs £623, respectively), these costs were offset by lower per-patient antifungal treatment costs (£799 vs £1,678, respectively). In the Spanish model, the DD approach was dominant with an average cost-effectiveness per persistent febrile episode of €32,671 versus €52,479 for the empiric approach.

Our modeled results are similar to those reported from clinical studies. Results from our study predict that fewer patients treated using a DD than an empiric approach would receive antifungal therapy. Similarly, Maertens et al found a decrease in antifungal administration using a preemptive compared to an empiric treatment approach. In this study, antifungal drug administration was reduced by 78% in patients treated using a preemptive compared to an empiric treatment approach.[@b6-ceor-8-275] Results reported by Girmenia et al[@b4-ceor-8-275] were also similar with a 43% decrease in antifungal drug administration with a DD (48 cases) compared to an empiric (84 cases) treatment approach.

The results of our analysis should be evaluated with the following limitations. First, a decision model was used to extrapolate and compile data in a mathematical and systematic manner to enable a comparative analysis because of limited published head-to-head clinical data comparing a DD versus an empiric treatment approach. Although a real-world analysis may more accurately reflect IFI incidence and mortality at a hospital in the People's Republic of China, the resources required to abstract real-world data from several hospitals located in different regions of the People's Republic of China was prohibitive. We therefore opted to construct a decision model incorporating data obtained from interviews of experts practicing at tier-3A hospitals located in four Chinese cities, representing geographically different locations and addressing variability in inputs such as IFI incidence, mortality, and duration of treatment in the sensitivity analyses. As we observed, there was considerable heterogeneity in physicians' treatment habits and considerable variability in resource utilization was noted for the four cities evaluated. Second, the clinical data used in the model were obtained from the published literature and supplemented with resource use and cost data obtained from top clinicians located at tier-3A hospitals in the People's Republic of China. These results may not be generalizable to a broader population. However, results from our analysis were consistent with published clinical studies, suggesting that a DD compared to an empiric treatment approach is cost saving for neutropenic fever in the People's Republic of China. Third, the incidence data incorporated into the model were for IFIs, not specifically invasive aspergillosis. Real-world incidence data for invasive aspergillosis within a particular clinical setting such as patients treated with myelosuppressive chemotherapy are scarce in the published literature. Therefore, our model was propagated using the IFI incidence reported by Hahn-Ast for patients with IFIs and neutropenia after myelosuppressive chemotherapy.[@b9-ceor-8-275] Although this may be an overestimate of the true incidence of invasive aspergillosis in this population, additional cost savings could be realized if the true incidence of invasive aspergillosis was lower than the IFI incidence incorporated into the model. Finally, we did not account for patients empirically initiated on antifungal therapy having their antifungal therapy discontinued early as a result of negative biomarker test and/or CT scan results. Although this would decrease the overall costs associated with the empiric approach, these patients would still be unnecessarily exposed to antifungal therapy and the risks associated with antifungal administration.

Conclusion
==========

Results from our model incorporating real-world data support a change in the treatment paradigm for IFIs from an empiric to a DD approach in the People's Republic of China for neutropenic patients with persistent fever unresponsive to broad-spectrum antibiotic therapy. Total costs were lower with similar survival for the cohort of neutropenic patients treated with a DD compared to an empiric approach, despite the additional costs of GM antigen and CT scan testing. Additional benefits could potentially be realized through standardization of a DD treatment protocol as collected data showed considerable variability in both DD and empiric treatment strategies throughout the People's Republic of China.

Interim findings for the Shanghai analyses were presented at the ISPOR 17th Annual European Congress, November 8--12, 2014, in Amsterdam, the Netherlands, as a poster presentation. The abstract for this presentation is available on <http://www.valueinhealthjournal.com/article/S1098-3015(14)04409-X/pdf>. Interim findings for the Beijing, Chengdu, and Guangzhou analyses were presented at the 2015 ISPOR Annual International Meeting, May 16--20, 2015, in Philadelphia, PA, USA, as a poster presentation. The abstract of this poster is available on <https://www.rti.org/publications/abstract.cfm?pubid=24212>.
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###### 

Clinical variables and data source of model inputs

  Input                                                                      Value                                   Reference
  -------------------------------------------------------------------------- --------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  IFI incidence (base-case, %)[a](#tfn1-ceor-8-275){ref-type="table-fn"}     10.9 (95% CI: 9--13)                    Hahn-Ast et al[@b9-ceor-8-275]
  **IFI identification, %**                                                                                          
  Empiric approach, % (range)                                                30 (29--31)                             Cordonnier et al;[@b3-ceor-8-275] Pagano et al[@b7-ceor-8-275]
  DD approach, %                                                             100                                     Assuming 100% DD test sensitivity
  Patients treated                                                           RR, 1.6987 for empiric vs DD approach   Cordonnier et al;[@b3-ceor-8-275] Morrissey et al[@b20-ceor-8-275]
  Patient weight, kg                                                         60.56                                   Body weight table[@b21-ceor-8-275]
  Diagnostic test sensitivity,[b](#tfn2-ceor-8-275){ref-type="table-fn"} %   GM test: 61.5%, CT scan: 44.0%          Pfeiffer et al;[@b16-ceor-8-275] Kami et al[@b15-ceor-8-275]
  **Overall survival, treatment effect**                                                                             
  Caspofungin                                                                HR: 0.589                               Hahn-Ast et al[@b9-ceor-8-275]
  Itraconazole                                                               HR: 1                                   Boogaerts et al;[@b10-ceor-8-275] Hahn-Ast et al[@b9-ceor-8-275][c](#tfn3-ceor-8-275){ref-type="table-fn"}
  Voriconazole                                                               HR: 0.589                               Hahn-Ast et al[@b9-ceor-8-275]
  IFI-related mortality, %                                                   28.6 (95% CI: 19--39)                   Hahn-Ast et al[@b9-ceor-8-275]
  Overall mortality, %                                                       10.7 (95% CI: 9--13)                    Hahn-Ast et al[@b9-ceor-8-275]
  Mortality without IFI, %                                                   7.6                                     Calculated[d](#tfn4-ceor-8-275){ref-type="table-fn"}
  Mortality with IFI, %                                                      36.2                                    Calculated[d](#tfn4-ceor-8-275){ref-type="table-fn"}
  Mortality, if treated with itraconazole, %                                 40.4                                    Boogaerts et al;[@b10-ceor-8-275] Hahn-Ast et al;[@b9-ceor-8-275] Calculated[d](#tfn4-ceor-8-275){ref-type="table-fn"}
  Mortality, if treated with caspofungin and voriconazole, %                 16.6                                    Calculated[d](#tfn4-ceor-8-275){ref-type="table-fn"}

**Notes:**

2002 European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) IFI definition.[@b22-ceor-8-275]

The average sensitivity of GM test and CT scan was used in the model.

Overall survival with itraconazole assumed to be the same as with amphotericin B; HR assumed to be 1.[@b10-ceor-8-275]

These values were calculated using the methods from Barnes et al, but were not taken from Barnes et al.[@b8-ceor-8-275]

**Abbreviations:** CI, confidence interval; CT, computed tomography; DD, diagnostic-driven; GM, galactomannan; HR, hazard ratio; IFI, invasive fungal infection; RR, relative risk.

###### 

Antifungal therapy and adverse event model inputs

  Drug                                                          Treatment approach   AF cost per day, ¥[b](#tfn7-ceor-8-275){ref-type="table-fn"}   ADM time, hours[c](#tfn8-ceor-8-275){ref-type="table-fn"}   Hepatotoxicity                              
  ------------------------------------------------------------- -------------------- -------------------------------------------------------------- ----------------------------------------------------------- ---------------- -------------- ----- ----- -----
  **Caspofungin**                                                                                                                                                                                                                                           
  Day 1: 70 mg IV                                               SH: 23.7             SH: 25.20                                                      SH: 30.2                                                    SH: 25.20        2,404          1.0   3     400
  Day 2 onward: 50 mg IV QD                                     BJ: 15.6             BJ: 19.00                                                      BJ: 19.0                                                    BJ: 19.00        1,858          1.0   3     400
  CD: 34.2                                                      CD: 41.00            CD: 17.1                                                       CD: 41.00                                                                                   3     400   
  GZ: 23.3                                                      GZ: 23.5             GZ: 22.0                                                       GZ: 23.5                                                                                    3     400   
  **Itraconazole**                                                                                                                                                                                                                                          
  Day 1 onward: 200 mg QD                                       SH: 23.7             SH: 25.17                                                      SH: 25.8                                                    SH: 25.17        1,096          0     3     400
  BJ: 39.9                                                      BJ: 21.25            BJ: 45.9                                                       BJ: 21.25                                                                                   3     400   
  CD: 12.5                                                      CD: 24.50            CD:9.3                                                         CD: 24.50                                                                                   3     400   
  GZ: 22.3                                                      GZ: 24.5             GZ: 20.3                                                       GZ: 24.5                                                                                    3     400   
  **Voriconazole[e](#tfn10-ceor-8-275){ref-type="table-fn"}**                                                                                                                                                                                               
  Day 1: 6 mg/kg IV Q12H                                        SH: 52.6             SH: 25.19                                                      SH: 44.0                                                    SH: 25.19        DD: 3,370.52   1.5   2.7   400
  BJ: 46.5                                                      BJ: 17.12            BJ: 35.1                                                       BJ: 17.12                                                   EA: 2,990.33                    2.7   400   
  Days 2--7: 4 mg/kg IV Q12H                                    CD: 53.3             CD: 25.08                                                      CD: 73.6                                                    CD: 25.08        DD: 1,685.26   1.5   2.7   400
  GZ: 54.5                                                      GZ: 47.83            GZ: 57.7                                                       GZ: 47.83                                                   EA: 1,495.17                    2.7   400   
  Day 8 onward: 300 mg PO                                                                                                                                                                                                        DD: 655.60     0     2.7   400
  Q12H                                                                                                                                                                                                                           EA: 610.49           2.7   400

**Notes:**

Antifungal treatment distribution, duration of DD and empiric approaches, and costs for treatment of hepatotoxicity were determined by KOLs in each city.

Daily cost of antifungal agents was provided by Pfizer China marketing research.

Administration time for antifungal agents remained the same as the UK model.[@b8-ceor-8-275] Hourly cost of a day ward nurse in the People's Republic of China was estimated at ¥15.19.[@b23-ceor-8-275]

Probability of patients experiencing adverse events was obtained from drug labels.[@b12-ceor-8-275]--[@b14-ceor-8-275]

Voriconazole cost is weighted based on the brand and generic drug proportion administered per treatment approach as determined during KOL interviews.

**Abbreviations:** ADM, administration; AF, antifungal; BJ, Beijing; CD, Chengdu; DD, diagnostic driven; EA, empiric approach; GZ, Guangzhou; IV, intravenous; KOL, key opinion leaders; PO, oral; Q12H, every 12 hours; QD, daily; SH, Shanghai; TX, treatment.

###### 

Model inputs for resource use[a](#tfn12-ceor-8-275){ref-type="table-fn"} in Shanghai, Beijing, Chengdu, and Guangzhou

  Resource                                                    Shanghai   Beijing     Chengdu   Guangzhou                                                                             
  ----------------------------------------------------------- ---------- ----------- --------- ----------- ----------- ------- ---------- ---------- ------- ----------- ----------- -------
  Neutrophil count                                            100/14.4   100/14.6    3         100/18.8    100/18.6    8       100/5.8    100/7.0    19      100/9.0     100/9.0     19
  Chest X-ray                                                 20.0/0.7   20.0/1.1    28        70/5.0      70.0/5.0    17      6.7/0.8    1.7/0.8    143     2.5/2.0     2.5/2.0     29
  Blood culture                                               100/4.6    100.0/3.0   30        90/5.7      90.0/5.7    35      86.7/2.5   76.7/2.5   125     93.3/4.0    93.3/4.0    70
  Urine culture                                               56.0/3.0   56.0/2.3    5         17/5.9      17.0/5.9    15      18.3/2.5   16.7/2.5   65      36.7/2.7    36.7/2.7    70
  N/P/R swabs                                                 78.0/4.0   68.0/2.8    50        40/1.9      40.0/1.9    35      20.0/3.2   15.0/3.2   395     47.5/6.4    47.5/6.4    395
  CT scan[c](#tfn14-ceor-8-275){ref-type="table-fn"}          100/2.8    90.0/2.2    170       100/7.0     100.0/7.2   180     90.0/3.1   75.0/4.5   250     100.0/6.9   100.0/6.9   350
  Abdominal ECHO                                              66.0/1.9   50.0/1.6    30        7.5/3.1     7.5/3.1     30      16.7/4.0   3.8/5.0    105     51.0/2.4    51.0/2.4    90
  Bronchoscopy                                                25.0/1.2   25.6/1.3    120       13/3.9      13.0/3.4    50      10/1.0     2.5/0      326     6.5/1.2     6.8/1.2     280
  BAL                                                         10.0/1.0   25.6/1.0    50        13/3.9      13.0/3.4    50      10.3/1.0   2.5/0      80      6.2/1.2     6.2/1.2     500
  GM test                                                     94.0/4.0   82.5/2.6    20        100/7.3     95.0/6.8    20      46.7/2.1   51.7/4.0   350     33.3/5.0    33.3/5.0    280
  PCR test                                                    20.0/1.0   25.0/1.0    180       0/0         0/0         100     0.5/0.0    0.0/0.0    180     0.0/0.0     0.0/0.0     230
  CMV PCR                                                     72.0/5.1   66.3/7.1    80        75/5.9      65.0/7.0    80      22.5/1.3   7.5/3.1    150     75.0/4.9    75.0/4.9    150
  Molecular test[d](#tfn15-ceor-8-275){ref-type="table-fn"}   36.0/1.6   25.0/1.0    80        64/5.4      64.0/5.4    80      25.0/1.2   20.0/0.6   80      75.0/4.1    75.0/4.1    80
  PET scan                                                    3.0/0.7    2.5/1.0     3,500     0.2/1.5     0.2/1.5     5,000   1.7/1.0    0.0/0.0    6,916   7.5/1.3     7.5/1.3     8,725
  Lung biopsy                                                 4.0/1.0    1.7/1.0     90        0.9/1.0     0.9/1.0     90      0.3/1.0    0.0/0.0    190     10.5/1.2    10.5/1.2    92
  Transbronchial biopsy                                       3.0/1.0    0.0/1.0     40        0.9/1.0     0.9/1.0     40      6.7/1.0    0.0/0.0    50      5.0/1.0     5.0/1.0     92
  Skin biopsy                                                 3.0/1.0    0.0/1.00    200       1.1/1.0     1.1/1.0     100     7.5/1.0    4.0/0.4    60      8/1.2       8.2/1.2     92

**Notes:**

General resource use by treatment approach as determined by key opinion leaders in the People's Republic of China.

Number of tests received per patient during the antifungal treatment period.

CT scan was of 1 area, no contrast.

Molecular tests included human herpes virus 6 PCR, herpes PCR, and adenovirus PCR.

**Abbreviations:** BAL, bronchoalveolar lavage; CMV, cytomegalovirus; CT, computed tomography ECHO, echography; GM, galactomannan; IFI, invasive fungal infection; N/P/R, nasal, pharyngeal, rectal; PCR, polymerase chain reaction; PET, positron emission tomography.

###### 

Modeled outcome results for DD and empiric IFI treatment strategies for four Chinese cities

  Outcomes                                Shanghai                   Beijing    Chengdu                   Guangzhou                                                                                                                
  --------------------------------------- -------------------------- ---------- ------------------------- ----------- -------------------------- --------- -------------------------- ---------- ----------- ---------- ---------- -----------
  **Costs, 2014 ¥**                                                                                                                                                                                                                
  Antifungal drug                         1,798.62                   3,108.57   −1,309.95                 1,349.87    2,294.12                   −944.25   2,609.77                   3,577.10   −967.33     2,046.47   3,350.21   −1,303.74
  GM testing                              111.36                     87.72      23.63                     146.40      128.44                     17.96     349.34                     717.31     −367.96     466.67     466.67     0.00
  Other medical resource use              1,321.41                   1,133.37   188.04                    2,396.93    2,440.13                   −43.20    1,671.76                   1,499.61   172.15      5,975.53   5,976.62   −1.09
  Adverse event                           0.65                       1.12       −0.47                     0.66        1.13                       −0.47     0.65                       1.09       −0.43       0.65       1.10       −0.45
  Total costs                             3,232.04                   4,330.79   −1,098.74                 3,893.86    4,863.82                   −969.96   4,631.53                   5,795.10   −1,163.58   8,489.32   9,794.60   −1,305.28
  **Clinical outcomes**                                                                                                                                                                                                            
  Initial patient cohort, n               1,000                      1,000                                1,000       1,000                                1,000                      1,000                  1,000      1,000      
  Pts treated with AF therapy, n          57                         98         −40                       57          98                         −40       57                         98         −40         57         98         −40
  IFIs diagnosed, n                       57                         33         25                        57          33                         25        57                         33         25          57         33         25
  Died, n                                 84                         92         −8                        86          98                         −11       83                         88         −5          84         91         −7
  Survived, %                             91.57                      90.76      0.81                      91.38       90.24                      1.14      91.72                      91.19      0.54        91.59      90.90      0.69
  Incremental cost per death avoided, ¥   −135.71 (DD cost saving)              −85.27 (DD cost saving)               −217.28 (DD cost saving)             −189.67 (DD cost saving)                                                

**Abbreviations:** AF, antifungal; DD, diagnostic driven; EA, empiric approach; GM, galactomannan; IFI, invasive fungal infection; Pts, patients.
